https://doi.org/10.4081/hmr.v3i3.559

The role of thalidomide as maintenance after autologous stem-cell transplantation in multiple myeloma

Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
Published: June 12, 2009
Abstract Views: 177
PDF: 185
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

A Maiolino
support@pagepress.org
V Tietsche de Moraes Hungria
M Nucci
C De Souza
Major progress was obtained in the last ten years for treatment of multiple myeloma (MM). High dose chemotherapy with autologous stem – cell transplant (ASCT) and new drugs as thalidomide, lenalidomide and bortezomibe have completely changed the scenario of MM treatment. ASCT becomes the mainstay of MM treatment for patients up to 65 years old. This strategy has been tested in randomized clinical trials and it proven that ASCT can improve overall survival of MM patients. Unfortunately, the large majority of these patients will relapse in few years after ASCT. Strategies of maintenance were developed trying to improve the ASCT results. Thalidomide has been tested in this setting on at least 4 randomized clinical trials with a significant impact on response rate, event free and overall survival.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Maiolino, A., Tietsche de Moraes Hungria, V., Nucci, M., & De Souza, C. (2009). The role of thalidomide as maintenance after autologous stem-cell transplantation in multiple myeloma. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.559
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).